JSA advised Serum Institute of India Private Limited (“Serum”), in its sale of 35% stake in Schott Poonawalla Private Limited (“Schott Poonawalla”) to TPG Scion Unit Trust (acting through its trustee Scion Trustee Limited) (“TPG”). Schott Poonawalla is a joint venture between Serum and the Schott group — pursuant to the proposed sale, the Schott group remains a majority shareholder in Schott Poonawalla, while Serum and TPG will hold 15.01% and 34.99%, respectively. The transaction was subject to CCI approval, which was successfully received last month. JSA was assisted by Gibson, Dunn & Crutcher LLP on the anti-bribery and anti-corruption-related aspects of the transaction.
SCHOTT Poonawalla is India’s largest injectables-focused drug containment solutions company, offering a comprehensive product portfolio of the highest quality for over two decades.
JSA transaction team comprised Lead Partner & National Corporate Lead, Iqbal Khan, Partner, Devika Menon, Senior Associate, Subbalaxmi S and Associate, Gunjan Singh.
JSA competition team comprised Partner and Chair, Competition Law, Nisha Kaur Uberoi, Principal Associate, Rahat Dhawan, Senior Associate, Rishi Kauntia and Associate, Cherian Chacko Manayath.
